3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Radiotherapy
2
Cyclophosphamide
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
talquetamab
1
obinutuzumab
1
Trastuzumab
1
Monatide (IMS 3015)
1
Maintenance
1
HMPL-013
1
Cetuximab
1
Blood Specimen Collection
1
Biological Assay
1
Ado-Trastuzumab Emtansine
1
AP 1903 reagent
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.